LumiraDx Receives FDA EUA for its COVID-19 Antibody Test
LumiraDx has announced receiving FDA EUA for its SARS-CoV-2 Ab test, which is used to help identify an adaptive immune response to SARS-CoV-2.
Read MorePosted by Chris Wolski | Aug 5, 2021 | Covid 19, POC Rapid Assays |
LumiraDx has announced receiving FDA EUA for its SARS-CoV-2 Ab test, which is used to help identify an adaptive immune response to SARS-CoV-2.
Read MorePosted by Chris Wolski | Aug 4, 2021 | Covid 19 |
Scientists at the CDC recently marked the importance of fixed tissue analysis for retrospective diagnosis of COVID-19 infection.
Read MorePosted by Chris Wolski | Aug 4, 2021 | Fertility Testing, POC Instruments |
At-home fertility testing is joining an array of routine tests that will be done increasingly at home, will impact clinical labs.
Read MorePosted by Chris Wolski | Aug 3, 2021 | Information Technology |
LigoLab Information System has announced that its TestDirectly patient platform supports laboratory services being provided in the home.
Read MorePosted by Chris Wolski | Jul 28, 2021 | Unknown Origin & Other Cancer Types, Urinalysis & Toxicology |
ADXBLADDER, a urinary biomarker test for bladder cancer, is currently undergoing clinical trials in the U.S.
Read More